0750 GMT - Parkway Life REIT is a "rare jewel" among Singapore REITs, as it offers highly visible, stable and sustainable earnings, DBS Group Research analysts write in a note. The REIT owns three private hospitals in Singapore, holding the majority of the market share, they say. Its recent unit-price correction implies an attractive forward 2026 yield of 5.0%, they add. A cross-check across four major valuation metrics suggests an overcorrection, positioning the units for a rebound, the analysts say. DBS raises the REIT's target price to S$4.80 from S$4.50 while maintaining a buy rating. Units are last 0.8% higher at S$3.73. (amanda.lee@wsj.com)
(END) Dow Jones Newswires
November 26, 2024 02:50 ET (07:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.